Adolescent and young adult (AYA) oncology has recently emerged as a new medical discipline with a focus on the needs and challenges around AYA cancer care. Improvements in all-age cancer treatments over the last 40 years has led to a doubling in overall survival for AYA patients with cancer, and >80% are expected to survive beyond 5 years. 1 Over this period, the incidence of cancer in AYAs has increased, meaning that there will be ever more AYA cancer survivors with the potential of many decades of life still to live. 2 The challenge is how to maintain this excellent survival rate and ensure the subsequent quality of survival.However, cancer mortality remains the leading cause of disease-related death for AYAs in North America. 2 In this issue of Cancer, Armenian and colleagues describe the profoundly elevated risk of premature death in AYAs with cancer that continues for well beyond 20 years after diagnosis. 3 Theirs is not an isolated series, as their data echo findings from Anderson et al and European AYA survivorship publications. [4][5][6] For the majority of patients, primary cancer recurrence is the most common cause of mortality in the early years of surveillance. It is of concern that the gain in improvement of overall survival outcomes for AYA patients has been significantly lower than the gains for both older and younger groups of patients with cancer. 7 Alongside this, there is a paucity of evidence delineating the subsequent mortality and morbidity for AYA survivors with which to underpin the design of survivorship programs. Although AYA survivorship outcomes are published for Hodgkin disease, testicular cancer, and sarcoma, these diagnoses represent <50% of the spectrum of all AYA cancers diagnosed each year. Similarly, the quality of survival in an aftercare setting has not been well evaluated. There is much work to be done.